Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RARE
  • CUSIP: N/A
  • Web: www.ultragenyx.com
Capitalization:
  • Market Cap: $2.37 billion
  • Outstanding Shares: 42,312,000
Average Prices:
  • 50 Day Moving Avg: $60.10
  • 200 Day Moving Avg: $71.59
  • 52 Week Range: $46.52 - $91.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.60
  • P/E Growth: -0.16
Sales & Book Value:
  • Annual Revenue: $133,000.00
  • Price / Sales: 17,786.95
  • Book Value: $11.56 per share
  • Price / Book: 4.84
Profitability:
  • EBIDTA: ($260,300,000.00)
  • Return on Equity: -46.68%
  • Return on Assets: -43.12%
Debt:
  • Current Ratio: 8.26%
  • Quick Ratio: 8.26%
Misc:
  • Average Volume: 578,362 shs.
  • Beta: 1.83
  • Short Ratio: 10.96
 

Frequently Asked Questions for Ultragenyx Pharmaceutical (NASDAQ:RARE)

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($1.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.71) by $0.08. During the same period in the prior year, the company posted ($1.35) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.

Where is Ultragenyx Pharmaceutical's stock going? Where will Ultragenyx Pharmaceutical's stock price be in 2017?

15 equities research analysts have issued 12 month target prices for Ultragenyx Pharmaceutical's shares. Their predictions range from $64.00 to $106.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $84.00 in the next twelve months. View Analyst Ratings for Ultragenyx Pharmaceutical.

What are analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:

  • 1. Canaccord Genuity analysts commented, "INSM’s Ph3 Arikayce NTM CONVERT trial data is due ~September of this year." (5/8/2017)
  • 2. Cowen and Company analysts commented, "Ultragenyx released data from a small Phase II trial of UX007 in Glut1 DS seizure." (3/23/2017)
  • 3. Jefferies Group LLC analysts commented, "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.Wang comments, "RARE 4Q16 EC was largely uneventful. Mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by YE17. We see overall favorable risk/reward heading into multiple data and regulatory catalysts in 2017, including KRN23 Ph3 data in adult XLH (1H17), BLA filing in the US, CHMP opinion in EU (2H17), Ace-ER Ph3 data in GNE myopathy (2H17)' RARE reported 4Q16 OpEx of $70.6M vs. our/consensus est of $74.8/69.9M. EPS was ($1.75) vs. our/consensus est of ($1.86/1.72). The company ended the quarter with $498.1M cash and guided that the cash should be sufficient to fund all clinical programs through Ph3 studies and potential launch. Mgmt guided to a continual increase in OpEx with a gradually slower YoY growth. Our $109 target is based on probability adjusted DCF. Risks include delay in EU conditional approval, less robust data, toxicity." (2/17/2017)
  • 4. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (1/12/2017)
  • 5. Leerink Swann analysts commented, "We maintain our OP rating on RARE with PT $85. A 64.8%/70.6% reduction in uGAGs (p50%/>60% reduction in dermatan and chondroitin sulfate (both uGAGs) within the first 2 weeks that was maintained until 24 weeks. Despite investors’ concerns of a small trial (n=12), 4 mg/kg rhGUS effectively demonstrated its efficacy as an enzyme in removing the accumulated substrate in MPS VII pts. Although the aggregate of functional improvements narrowly missed stat. sig. (p=0.0527), we believe clinical improvements engenderd by rhGUS makes a strong case for the therapy. The summation of scores from functional assessments (including 6-minute walk test/6MWT and visual acuity) showed a positive trend. With regards to the miss on stat. sig., we agree with mgmt. that individual assessments paint a clearer picture of therapeutic benefit in pts. and remind investors that neither regulatory agencies required stat. sig. in earlier discussions. Furthermore, whereas functionality in pts. progressively worsen, noteworthy improvements in 6MWT (especially 60+ meters benefit in 3/9 pts. over 24 weeks) and ~2/3 of pts." (7/15/2016)

Are investors shorting Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 5,336,808 shares, a decline of 3.8% from the March 31st total of 5,545,725 shares. Based on an average daily volume of 542,306 shares, the short-interest ratio is currently 9.8 days.

Who are some of Ultragenyx Pharmaceutical's key competitors?

Who owns Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.64%), Wellington Management Group LLP (10.98%), BlackRock Inc. (7.59%), Vanguard Group Inc. (7.18%), State Street Corp (2.99%) and Columbia Wanger Asset Management LLC (2.97%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Who sold Ultragenyx Pharmaceutical stock? Who is selling Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Wells Fargo & Company MN, State Street Corp, Alliancebernstein L.P., Iguana Healthcare Management LLC, AXA, Morgan Stanley and Hood River Capital Management LLC. Company insiders that have sold Ultragenyx Pharmaceutical stock in the last year include Emil D Kakkis, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Who bought Ultragenyx Pharmaceutical stock? Who is buying Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Vanguard Group Inc., Bank of Montreal Can, Point72 Asset Management L.P., Quantitative Investment Management LLC, Columbia Wanger Asset Management LLC and Aureus Asset Management LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy Ultragenyx Pharmaceutical stock?

Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ultragenyx Pharmaceutical stock cost?

One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $55.91.

Analyst Ratings

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $84.00 (50.24% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017Canaccord GenuityReiterated RatingBuyLowView Rating Details
5/8/2017Morgan StanleyLower Price TargetEqual Weight$84.00 -> $79.00LowView Rating Details
5/8/2017Jefferies Group LLCBoost Price TargetHold$66.00 -> $68.00LowView Rating Details
4/19/2017Robert W. BairdReiterated RatingOutperform$90.00MediumView Rating Details
4/19/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
4/19/2017SunTrust Banks, Inc.Boost Price TargetBuy$100.00 -> $105.00MediumView Rating Details
4/19/2017WedbushDowngradeOutperform -> Neutral$80.00 -> $75.00HighView Rating Details
4/19/2017HC WainwrightDowngradeBuy -> Neutral$88.00 -> $72.00HighView Rating Details
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> NeutralHighView Rating Details
11/30/2016Citigroup IncDowngradeNeutral -> SellN/AView Rating Details
11/14/2016Leerink SwannReiterated RatingOutperform$94.00 -> $90.00N/AView Rating Details
11/9/2016JPMorgan Chase & Co.Reiterated RatingBuy$106.00N/AView Rating Details
9/14/2016Credit Suisse Group AGReiterated RatingBuy$101.00N/AView Rating Details
6/28/2016Bank of America CorpInitiated CoverageBuy$72.00N/AView Rating Details
6/8/2016JMP SecuritiesReiterated RatingBuy$80.00 -> $84.00N/AView Rating Details
2/9/2016Sterne Agee CRTInitiated CoverageBuyN/AView Rating Details
12/1/2015Stifel NicolausInitiated CoverageBuy -> Buy$125.00 -> $125.00N/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageOutperform$125.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Earnings by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Earnings History by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($1.71)($1.63)$0.05 millionViewListenView Earnings Details
2/16/2017Q4 2016($1.72)($1.75)$0.05 million$0.01 millionViewN/AView Earnings Details
11/7/2016Q3($1.53)($1.64)$7.60 million$0.11 millionViewListenView Earnings Details
8/8/2016Q2($1.44)($1.46)$0.02 millionViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
2017 EPS Consensus Estimate: ($7.15)
2018 EPS Consensus Estimate: ($7.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.82)($1.69)($1.75)
Q2 20174($1.93)($1.59)($1.76)
Q3 20174($2.01)($1.62)($1.81)
Q4 20174($2.09)($1.67)($1.83)
Q1 20181($1.99)($1.99)($1.99)
Q2 20181($1.97)($1.97)($1.97)
Q3 20181($1.91)($1.91)($1.91)
Q4 20181($1.89)($1.89)($1.89)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 96.35%
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Theodore Alan HuizengaVPSell480$57.46$27,580.80View SEC Filing  
3/9/2017Theodore Alan HuizengaInsiderSell2,500$86.34$215,850.00View SEC Filing  
3/2/2017Shalini SharpCFOSell12,000$90.10$1,081,200.00View SEC Filing  
2/27/2017Shalini SharpCFOSell12,000$80.14$961,680.00View SEC Filing  
12/5/2016William AliskiDirectorSell6,000$78.19$469,140.00View SEC Filing  
11/9/2016Shalini SharpCFOSell24,000$71.20$1,708,800.00View SEC Filing  
10/19/2016Shalini SharpCFOSell12,000$61.40$736,800.00View SEC Filing  
10/14/2016Emil D KakkisCEOSell20,000$63.02$1,260,400.00View SEC Filing  
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Source:
DateHeadline
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) VP Theodore Alan Huizenga Sells 480 Shares
www.americanbankingnews.com - May 26 at 8:28 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Ultragenyx Pharmaceutical Inc (RARE) to Post -$1.72 Earnings Per Share
www.americanbankingnews.com - May 25 at 10:28 AM
globenewswire.com logoUltragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License ...
globenewswire.com - May 23 at 9:41 AM
streetinsider.com logoUltragenyx Pharma (RARE) Says Recombinant Human Beta-Glucuronidase BLA and MAA Filed and Accepted for Review; FDA Grants Priority Review Status
www.streetinsider.com - May 23 at 9:41 AM
finance.yahoo.com logoUltragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status
finance.yahoo.com - May 23 at 9:41 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 7:56 AM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - Business Wire (press release)
www.businesswire.com - May 16 at 9:39 AM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc.
finance.yahoo.com - May 16 at 9:39 AM
finance.yahoo.com logoUltragenyx to Present at Bank of America Merrill Lynch Healthcare Conference
finance.yahoo.com - May 11 at 7:56 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Receives "Buy" Rating from Citigroup Inc
www.americanbankingnews.com - May 11 at 5:58 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Expected to Post Q2 2017 Earnings of ($1.59) Per Share
www.americanbankingnews.com - May 11 at 7:50 AM
globenewswire.com logoUltragenyx to Present at Bank of America Merrill Lynch Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - May 10 at 7:40 PM
americanbankingnews.com logoSunTrust Banks Comments on Ultragenyx Pharmaceutical Inc's Q2 2017 Earnings (RARE)
www.americanbankingnews.com - May 10 at 8:08 AM
americanbankingnews.com logoSunTrust Banks Research Analysts Increase Earnings Estimates for Ultragenyx Pharmaceutical Inc (RARE)
www.americanbankingnews.com - May 9 at 12:42 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - May 8 at 10:16 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Given "Equal Weight" Rating at Morgan Stanley
www.americanbankingnews.com - May 8 at 7:46 PM
americanbankingnews.com logoJefferies Group LLC Reiterates Hold Rating for Ultragenyx Pharmaceutical Inc (RARE)
www.americanbankingnews.com - May 8 at 12:44 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Sees Significant Decline in Short Interest
www.americanbankingnews.com - May 6 at 7:44 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 6 at 12:17 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Posts Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 5 at 11:52 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - May 5 at 10:00 PM
finance.yahoo.com logoEdited Transcript of RARE earnings conference call or presentation 4-May-17 9:00pm GMT
finance.yahoo.com - May 5 at 7:43 PM
finance.yahoo.com logoUltragenyx reports 1Q loss
finance.yahoo.com - May 5 at 8:20 AM
globenewswire.com logoUltragenyx Reports First Quarter 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - May 5 at 12:42 AM
finance.yahoo.com logoUltragenyx Reports First Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - May 4 at 7:40 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Expected to Post Quarterly Sales of $70,000.00
www.americanbankingnews.com - May 4 at 2:42 PM
americanbankingnews.com logoUltragenyx Pharmaceutical (RARE) Earning Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 12:52 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 2 at 10:14 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Expected to Announce Earnings of -$1.70 Per Share
www.americanbankingnews.com - May 2 at 7:42 AM
globenewswire.com logoUltragenyx to Host Conference Call for First Quarter 2017 Financial Results and Corporate Update - GlobeNewswire (press release)
globenewswire.com - April 29 at 7:51 PM
finance.yahoo.com logoUltragenyx to Host Conference Call for First Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - April 28 at 8:29 PM
streetinsider.com logoUltragenyx Pharma (RARE) Begins Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement
www.streetinsider.com - April 27 at 7:53 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Ultragenyx Pharma, Chimerix, Coherus Biosciences, and Omeros - PR Newswire (press release)
www.prnewswire.com - April 27 at 10:46 AM
streetinsider.com logoUltragenyx Pharma (RARE) Begins Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement - StreetInsider.com
www.streetinsider.com - April 27 at 10:46 AM
finance.yahoo.com logoUltragenyx Initiates Global Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement Disorders
finance.yahoo.com - April 27 at 10:46 AM
americanbankingnews.com logoUltragenyx Pharmaceutical (RARE) Earning Somewhat Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 27 at 1:13 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 1:01 PM
americanbankingnews.com logoUltragenyx Pharmaceutical (RARE) Getting Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 23 at 9:16 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Lowered to "Neutral" at Wedbush
www.americanbankingnews.com - April 23 at 9:15 AM
americanbankingnews.com logoCanaccord Genuity Reiterates Buy Rating for Ultragenyx Pharmaceutical Inc (RARE)
www.americanbankingnews.com - April 23 at 7:26 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc Forecasted to Earn FY2018 Earnings of ($5.59) Per Share (RARE)
www.americanbankingnews.com - April 21 at 4:50 PM
americanbankingnews.com logoQ1 2018 EPS Estimates for Ultragenyx Pharmaceutical Inc (RARE) Cut by Analyst
www.americanbankingnews.com - April 21 at 4:05 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Receives Outperform Rating from Robert W. Baird
www.americanbankingnews.com - April 19 at 11:57 PM
americanbankingnews.com logoUltragenyx Pharmaceutical's (RARE) "Outperform" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - April 19 at 10:35 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Receives "Buy" Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - April 19 at 10:01 PM
nasdaq.com logoUltragenyx's Hypophosphatemia Drug Succeeds in Phase III
www.nasdaq.com - April 19 at 7:25 PM
finance.yahoo.com logoBiotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data
finance.yahoo.com - April 19 at 7:25 PM
finance.yahoo.com logoThe Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data
finance.yahoo.com - April 19 at 7:25 PM
finance.yahoo.com logoWhy Ultragenyx Pharmaceutical Stock Is Spiking Today
finance.yahoo.com - April 19 at 7:25 PM
finance.yahoo.com logoAnalyst Sees Ultragenyx Shares Range Bound Despite Positive Data
finance.yahoo.com - April 19 at 7:25 PM

Social

Chart

Ultragenyx Pharmaceutical (RARE) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff